US FDA Nod for Indian Drug Maker Jubilant's Anti-Infection Drug Levofloxacin

by Dr. Trupti Shirole on  June 26, 2015 at 5:44 AM Drug News
RSS Email Print This Page Comment
Font : A-A+

Leading Indian drug maker Jubilant Life Sciences has announced that it had received approval of the US Food and Drug Administration (FDA) for its tablets used in treating adults for various infections.
US FDA Nod for Indian Drug Maker Jubilant's Anti-Infection Drug Levofloxacin
US FDA Nod for Indian Drug Maker Jubilant's Anti-Infection Drug Levofloxacin

The company said, "Levofloxacin tablets are the generic version of Levaquin of Ortho-McNeil, used for treating infections such as pneumonia, sinusitis, bronchitis, prostatitis, urinary tract and inhalational anthrax."

The market size for Levofloxacin is estimated to be $28 million (Rs.179 crore) per annum.

The company, which had 806 filings for formulations till March 31, 2015, got approval for 368 of them from various regions worldwide, including 72 from FDA.

The Noida-based integrated drug maker, Jubilant, manufactures and supplies active pharmaceutical ingredients, solid dosage formulations, specialty pharmaceuticals and life science ingredients. The firm also provides services in contract manufacturing and drug discovery solutions to global firms from its 10 production units in India, Canada and the US.

Source: IANS

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Signature Drug Toxicity 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive